Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5317099 | 1.00 | POLB (0.32) | POLB | |
| SCHEMBL14100048 | 0.83 | — | — | |
| SCHEMBL5313897 | 0.79 | POLB (0.33) | POLB | |
| SCHEMBL4582685 | 0.79 | POLB (0.33) | POLB | |
| Hydrochloric Acid SCHEMBL4582681 | 0.78 | POLB (0.32) | POLB | |
| SCHEMBL8693335 | 0.76 | POLB (0.37) | POLB | |
| SCHEMBL8693325 | 0.76 | POLB (0.37) | POLB | |
| Upenazime SCHEMBL1477985 | 0.76 | POLB (0.37) | POLB | |
| SCHEMBL451140 | 0.75 | GAA (0.30) | — | |
| SCHEMBL15135657 | 0.74 | POLB (0.36) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0629617-B2 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INT BV (NL) | 2007-09-26 | — | — | EP | claimed |
| EP-0629617-B1 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INT BV (NL) | 1998-04-29 | — | — | EP | claimed |
| US-20250019418-A1 | SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES | OHIO STATE INNOVATION FOUNDATION | 2025-01-16 | — | — | US | disclosed |
| CN-111225679-B | Novel peptide-based cancer imaging agents | 俄亥俄州创新基金会 | 2024-03-29 | — | — | CN | disclosed |
| US-20230338584-A1 | NOVEL PEPTIDE-BASED CANCER IMAGING AGENTS | OHIO STATE INNOVATION FOUNDATION | 2023-10-26 | — | — | US | disclosed |
| WO-2023086152-A1 | SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES | OHIO STATE INNOVATION FOUNDATION (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11419951-B2 | Peptide-based cancer imaging agents | OHIO STATE INNOVATION FOUNDATION (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220218834-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-14 | — | — | US | disclosed |
| US-11358982-B2 | Methods for the iodination of biomolecules | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3972646-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019418-A1 | SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES | MB, HMBS, HCCS | POLB 1439/4885 |
| US-11358982-B2 | Methods for the iodination of biomolecules | TPO, LPO, MPO | POLB 1053/4885 |
| US-20220218834-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | HBG1, HBG2, LPO | POLB 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.